跳转至内容
Merck
  • Modeling retinitis pigmentosa through patient-derived retinal organoids.

Modeling retinitis pigmentosa through patient-derived retinal organoids.

STAR protocols (2021-04-27)
Yan-Ping Li, Wen-Li Deng, Zi-Bing Jin
摘要

Human-induced pluripotent stem cells (hiPSCs) can be differentiated into well-structured retinal organoids. In this protocol, we successfully established 3D retinae from patient-derived hiPSCs and built the retinitis pigmentosa model in vitro. Moreover, mutation in the retinitis pigmentosa GTPase regulator (RPGR) gene was corrected by CRISPR-Cas9 gene editing, which rescued the structure and function of the 3D retinae. For complete details on the use and execution of this protocol, please refer to Deng et al. (2018).

材料
货号
品牌
产品描述

Sigma-Aldrich
二甲基亚砜, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Roche
DNase I, from bovine pancreas
Sigma-Aldrich
视黄酸, ≥98% (HPLC), powder
Sigma-Aldrich
MEM 非必需氨基酸溶液 (100×), without L-glutamine, liquid, sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
1-硫代甘油, liquid, BioReagent, suitable for cell culture, ≥97% (titration)
Sigma-Aldrich
G 418 二硫酸盐, suitable for plant cell culture, BioReagent
Sigma-Aldrich
单克隆抗-视蛋白 小鼠抗, clone RET-P1, ascites fluid